Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development and application of classical swine fever virus monoclonal antibodies derived from single B cells
Veterinary Research Open Access 16 October 2023
-
Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
Cell & Bioscience Open Access 07 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reichert, J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19, 819–822 (2001).
Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110–118 (2002).
Reichert, J. & Pavolu, A. Monoclonal antibodies market. Nat. Rev. Drug Discov. 3, 383–384 (2004).
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Milstein, C. The hybridoma revolution: an offshoot of basic research. Bioessays 21, 966–973 (1999).
Morrison, S.L. et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).
Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).
Cole, S.P., Campling, B.G., Atlaw, T., Kozbor, D. & Roder, J.C. Human monoclonal antibodies. Mol. Cell. Biochem. 62, 109–120 (1984).
Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311 (1986).
Pasqualini, R. & Arap, W. Hybridoma-free generation of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 101, 257–259 (2004).
Inglis, T.J.J. et al. Monoclonal antiendotoxin agent HA-1A (Centoxin). Lancet 341, 303 (1993).
Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
Fleming, T. (ed.). Red Book (Thomson PDR, Montvale, New Jersey, 2004).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).
Acknowledgements
The authors gratefully acknowledge the assistance of the companies that provided survey data. We also thank H. Pujar for reviewing the manuscript and for providing helpful comments and suggestions.
Author information
Authors and Affiliations
Author notes
Clark J. Rosensweig and Matthew C. Dewitz were summer interns at CSDD.
Rights and permissions
About this article
Cite this article
Reichert, J., Rosensweig, C., Faden, L. et al. Monoclonal antibody successes in the clinic. Nat Biotechnol 23, 1073–1078 (2005). https://doi.org/10.1038/nbt0905-1073
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1073
This article is cited by
-
Development and application of classical swine fever virus monoclonal antibodies derived from single B cells
Veterinary Research (2023)
-
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity
Nature Cancer (2022)
-
A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer
Breast Cancer (2022)
-
Development of rolled scaffold for high-density adherent cell culture
Biomedical Microdevices (2020)
-
Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
Cell & Bioscience (2019)
